OBJECTIVE: To determine which hydration (saline, saline + mannitol, or saline + furosemide) is associated with least cisplatin nephrotoxicity. METHODS: We randomized 49 women who receivedcisplatin (75 mg/m(2) every 3 weeks) into one of the three hydration arms. The 24-h creatinine clearance was measured before and on day 6 after cisplatin infusion. The patients of each arm received 2 l of saline hydration. In the saline + furosemide arm, 40 mg of furosemide was given after hydration. In the saline + mannitol arm, 50 g of mannitol was mixed with the cisplatin. RESULTS: For the first cycle of chemotherapy, 15 women were randomized to saline, 17 to saline + furosemide, and 17 to saline + mannitol. For each group, the creatinine clearances before cisplatin infusion were (means+/-SD, milliliters per minute) 84.5+/-26.8, 82.5+/-24.0 and 87.4+/-25.6, and after cisplatin infusion were 79.1+/-31.9, 68.7+/-21.5, and 56.4+/-22.9, respectively. The decreases in creatinine clearance were similar between the saline group and the saline + furosemide group ( P=0.66), but different between the saline + mannitol group and the saline group ( P=0.02) or the saline + furosemide group ( P=0.02). As each woman received multiple courses of cisplatin, 15 who received saline contributed 41 paired datasets, 17 who received saline + furosemide contributed 49 paired datasets, and 17 who received saline + mannitol contributed 36 paired datasets showed similar patterns. CONCLUSIONS: Hydration with saline or saline + furosemide appears to be associated with less cisplatin nephrotoxicity than saline + mannitol.
RCT Entities:
OBJECTIVE: To determine which hydration (saline, saline + mannitol, or saline + furosemide) is associated with least cisplatinnephrotoxicity. METHODS: We randomized 49 women who received cisplatin (75 mg/m(2) every 3 weeks) into one of the three hydration arms. The 24-h creatinine clearance was measured before and on day 6 after cisplatin infusion. The patients of each arm received 2 l of saline hydration. In the saline + furosemide arm, 40 mg of furosemide was given after hydration. In the saline + mannitol arm, 50 g of mannitol was mixed with the cisplatin. RESULTS: For the first cycle of chemotherapy, 15 women were randomized to saline, 17 to saline + furosemide, and 17 to saline + mannitol. For each group, the creatinine clearances before cisplatin infusion were (means+/-SD, milliliters per minute) 84.5+/-26.8, 82.5+/-24.0 and 87.4+/-25.6, and after cisplatin infusion were 79.1+/-31.9, 68.7+/-21.5, and 56.4+/-22.9, respectively. The decreases in creatinine clearance were similar between the saline group and the saline + furosemide group ( P=0.66), but different between the saline + mannitol group and the saline group ( P=0.02) or the saline + furosemide group ( P=0.02). As each woman received multiple courses of cisplatin, 15 who received saline contributed 41 paired datasets, 17 who received saline + furosemide contributed 49 paired datasets, and 17 who received saline + mannitol contributed 36 paired datasets showed similar patterns. CONCLUSIONS: Hydration with saline or saline + furosemide appears to be associated with less cisplatinnephrotoxicity than saline + mannitol.
Authors: Matthew R Trendowski; Omar El-Charif; Mark J Ratain; Patrick Monahan; Zepeng Mu; Heather E Wheeler; Paul C Dinh; Darren R Feldman; Shirin Ardeshir-Rouhani-Fard; Robert J Hamilton; David J Vaughn; Chunkit Fung; Christian Kollmannsberger; Taisei Mushiroda; Michiaki Kubo; Robyn Hannigan; Frederick Strathmann; Lawrence H Einhorn; Sophie D Fossa; Lois B Travis; M Eileen Dolan Journal: Clin Cancer Res Date: 2019-07-11 Impact factor: 12.531
Authors: Daniel J Crona; Aimee Faso; Tomohiro F Nishijima; Kathleen A McGraw; Matthew D Galsky; Matthew I Milowsky Journal: Oncologist Date: 2017-04-24
Authors: Doralina L Anghelescu; Christina-Lin Brown; Andrew J Murphy; Andrew M Davidoff; Paxton V Dickson; Evan S Glazer; Zachary E Stiles; Michael W Bishop; Luke Douthitt; Jeremiah L Deneve Journal: Ann Surg Oncol Date: 2018-10-23 Impact factor: 5.344
Authors: P Espandiari; B Rosenzweig; J Zhang; Y Zhou; L Schnackenberg; V S Vaidya; P L Goering; R P Brown; J V Bonventre; K Mahjoob; R D Holland; R D Beger; K Thompson; J Hanig; N Sadrieh Journal: J Appl Toxicol Date: 2010-03 Impact factor: 3.446